Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

108 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II trial of gefitinib in recurrent glioblastoma.
Rich JN, Reardon DA, Peery T, Dowell JM, Quinn JA, Penne KL, Wikstrand CJ, Van Duyn LB, Dancey JE, McLendon RE, Kao JC, Stenzel TT, Ahmed Rasheed BK, Tourt-Uhlig SE, Herndon JE 2nd, Vredenburgh JJ, Sampson JH, Friedman AH, Bigner DD, Friedman HS. Rich JN, et al. Among authors: wikstrand cj. J Clin Oncol. 2004 Jan 1;22(1):133-42. doi: 10.1200/JCO.2004.08.110. Epub 2003 Nov 24. J Clin Oncol. 2004. PMID: 14638850 Clinical Trial.
Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors.
Sampson JH, Akabani G, Archer GE, Bigner DD, Berger MS, Friedman AH, Friedman HS, Herndon JE 2nd, Kunwar S, Marcus S, McLendon RE, Paolino A, Penne K, Provenzale J, Quinn J, Reardon DA, Rich J, Stenzel T, Tourt-Uhlig S, Wikstrand C, Wong T, Williams R, Yuan F, Zalutsky MR, Pastan I. Sampson JH, et al. J Neurooncol. 2003 Oct;65(1):27-35. doi: 10.1023/a:1026290315809. J Neurooncol. 2003. PMID: 14649883 Clinical Trial.
Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas.
Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE 2nd, Cokgor I, McLendon RE, Pegram CN, Provenzale JM, Quinn JA, Rich JN, Regalado LV, Sampson JH, Shafman TD, Wikstrand CJ, Wong TZ, Zhao XG, Zalutsky MR, Bigner DD. Reardon DA, et al. Among authors: wikstrand cj. J Clin Oncol. 2002 Mar 1;20(5):1389-97. doi: 10.1200/JCO.2002.20.5.1389. J Clin Oncol. 2002. PMID: 11870184 Clinical Trial.
Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results.
Bigner DD, Brown MT, Friedman AH, Coleman RE, Akabani G, Friedman HS, Thorstad WL, McLendon RE, Bigner SH, Zhao XG, Pegram CN, Wikstrand CJ, Herndon JE 2nd, Vick NA, Paleologos N, Cokgor I, Provenzale JM, Zalutsky MR. Bigner DD, et al. Among authors: wikstrand cj. J Clin Oncol. 1998 Jun;16(6):2202-12. doi: 10.1200/JCO.1998.16.6.2202. J Clin Oncol. 1998. PMID: 9626222 Clinical Trial.
Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results.
Brown MT, Coleman RE, Friedman AH, Friedman HS, McLendon RE, Reiman R, Felsberg GJ, Tien RD, Bigner SH, Zalutsky MR, Zhao XG, Wikstrand CJ, Pegram CN, Herndon JE 2nd, Vick NA, Paleologos N, Fredericks RK, Schold SC Jr, Bigner DD. Brown MT, et al. Among authors: wikstrand cj. Clin Cancer Res. 1996 Jun;2(6):963-72. Clin Cancer Res. 1996. PMID: 9816257 Clinical Trial.
Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas.
Cokgor I, Akabani G, Kuan CT, Friedman HS, Friedman AH, Coleman RE, McLendon RE, Bigner SH, Zhao XG, Garcia-Turner AM, Pegram CN, Wikstrand CJ, Shafman TD, Herndon JE 2nd, Provenzale JM, Zalutsky MR, Bigner DD. Cokgor I, et al. Among authors: wikstrand cj. J Clin Oncol. 2000 Nov 15;18(22):3862-72. doi: 10.1200/JCO.2000.18.22.3862. J Clin Oncol. 2000. PMID: 11078500 Clinical Trial.
Tumor resection cavity administered iodine-131-labeled antitenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspects.
McLendon RE, Akabani G, Friedman HS, Reardon DA, Cleveland L, Cokgor I, Herndon JE 2nd, Wikstrand C, Boulton ST, Friedman AH, Bigner DD, Zalutsky MR. McLendon RE, et al. Nucl Med Biol. 2007 May;34(4):405-13. doi: 10.1016/j.nucmedbio.2007.01.009. Epub 2007 Mar 30. Nucl Med Biol. 2007. PMID: 17499730 Free PMC article.
Monoclonal antibodies for brain tumour treatment.
Boskovitz A, Wikstrand CJ, Kuan CT, Zalutsky MR, Reardon DA, Bigner DD. Boskovitz A, et al. Among authors: wikstrand cj. Expert Opin Biol Ther. 2004 Sep;4(9):1453-71. doi: 10.1517/14712598.4.9.1453. Expert Opin Biol Ther. 2004. PMID: 15335313 Review.
Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition.
Goudar RK, Shi Q, Hjelmeland MD, Keir ST, McLendon RE, Wikstrand CJ, Reese ED, Conrad CA, Traxler P, Lane HA, Reardon DA, Cavenee WK, Wang XF, Bigner DD, Friedman HS, Rich JN. Goudar RK, et al. Among authors: wikstrand cj. Mol Cancer Ther. 2005 Jan;4(1):101-12. Mol Cancer Ther. 2005. PMID: 15657358
108 results